Professional Summary »
Practice Locations »
Referring Physicians »
Professional Summary
Education & Certifications
- Board Certification: United Council for Neurologic Subspecialties, Neuro-Oncology (2023)
- Board Certification: American Board of Psychiatry and Neurology, Neurology with Special Qualifications in Child Neurology (2020)
- Fellowship: Stanford Hospital and Clinics Neuro-Immunology-Oncology (2022) CA
- Fellowship: Stanford Hospital and Clinics Neuro-Oncology Fellowship (2021) CA
- Residency: Washington University in St. Louis GME Verifications (2020) MO
- Internship: Washington University in St. Louis GME Verifications (2017) MO
- Medical Education: Vanderbilt University School of Medicine (2015) TN
- Pediatric Neuro-Oncology Fellow, Lucile Packard Children's Hospital at Stanford University
- MD, Vanderbilt University School of Medicine, Doctor of Medicine (2015)
- BS and BA, Southern Methodist University, Biochemistry and History (2011)
Honors & Awards
- Cal Turner Program for Moral Leadership in Professions Fellow, Cal Turner Program (2014)
- Phi Beta Kappa, Phi Beta Kappa (2010)
- SMU President's Scholar, Southern Methodist University (2007-2011)
- The Leonard Tow Humanism in Medicine Award, Arnold P. Gold Foundation (2015)
Memberships
- Member, Children's Oncology Group (2021 - Present)
- Member, Society of Neuro-Oncology (2020 - Present)
- Member, Child Neurology Society (2017 - Present)
- Member, American Academy of Neurology (2017 - Present)
- Member, Gold Humanism Honor Society (2015 - Present)
- Member, Phi Beta Kappa (2010 - Present)
Publications
-
SINGLE CELL RNA SEQUENCING FROM THE CSF OF SUBJECTS WITH H3K27M+DIPG/DMG TREATED WITH GD2 CAR T-CELLULAR THERAPY
Mochizuki, A., Ramakrishna, S., Good, Z., Patel, S., Chinnasamy, H., Yeom, K., … Monje, M. (2021). SINGLE CELL RNA SEQUENCING FROM THE CSF OF SUBJECTS WITH H3K27M+DIPG/DMG TREATED WITH GD2 CAR T-CELLULAR THERAPY. NEURO-ONCOLOGY. OXFORD UNIV PRESS INC. -
GD2 CAR T-CELLS MEDIATE CLINICAL ACTIVITY AND MANAGEABLE TOXICITY IN CHILDREN AND YOUNG ADULTS WITH H3K27M-MUTATED DIPG AND SPINAL CORD DMG
Majzner, R., Ramakrishna, S., Mochizuki, A., Patel, S., Chinnasamy, H., Yeom, K., … Monje, M. (2021). GD2 CAR T-CELLS MEDIATE CLINICAL ACTIVITY AND MANAGEABLE TOXICITY IN CHILDREN AND YOUNG ADULTS WITH H3K27M-MUTATED DIPG AND SPINAL CORD DMG. NEURO-ONCOLOGY. OXFORD UNIV PRESS INC. -
"STROKE MIMICS" ARE NOT BENIGN IN IMMUNOCOMPROMISED CHILDREN
Mahdi, J., Bach, A., Smith, A., Tomko, S., Fields, M., Griffith, J., … Agner, S. (2021). "STROKE MIMICS" ARE NOT BENIGN IN IMMUNOCOMPROMISED CHILDREN. NEURO-ONCOLOGY. OXFORD UNIV PRESS INC. -
GD2 CAR T cells mediate clinical activity and manageable toxicity in children and young adults with DIPG and H3K27M-mutated diffuse midline gliomas.
Majzner, R. G., Ramakrishna, S., Mochizuki, A., Patel, S., Chinnasamy, H., Yeom, K., … Monje, M. (2021). GD2 CAR T cells mediate clinical activity and manageable toxicity in children and young adults with DIPG and H3K27M-mutated diffuse midline gliomas. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH. -
Nonoptic pathway tumors in children with neurofibromatosis type 1.
Mahdi, J., Goyal, M. S., Griffith, J., Morris, S. M., & Gutmann, D. H. (2020). Nonoptic pathway tumors in children with neurofibromatosis type 1. Neurology, 95(8), e1052–e1059. -
A multi-institutional study of brainstem gliomas in children with neurofibromatosis type 1.
Mahdi, J., Shah, A. C., Sato, A., Morris, S. M., McKinstry, R. C., Listernick, R., … Gutmann, D. H. (2017). A multi-institutional study of brainstem gliomas in children with neurofibromatosis type 1. Neurology, 88(16), 1584–1589. -
Increased prevalence of brain tumors classified as T2 hyperintensities in neurofibromatosis 1.
Griffith, J. L., Morris, S. M., Mahdi, J., Goyal, M. S., Hershey, T., & Gutmann, D. H. (2018). Increased prevalence of brain tumors classified as T2 hyperintensities in neurofibromatosis 1. Neurology. Clinical Practice, 8(4), 283–291. -
Pediatric Acute Stroke Protocol Activation in a Children's Hospital Emergency Department.
Ladner, T. R., Mahdi, J., Gindville, M. C., Gordon, A., Harris, Z. L., Crossman, K., … Jordan, L. C. (2015). Pediatric Acute Stroke Protocol Activation in a Children's Hospital Emergency Department. Stroke, 46(8), 2328–31. -
A multispecialty pediatric neurovascular conference: a model for interdisciplinary management of complex disease.
Ladner, T. R., Mahdi, J., Attia, A., Froehler, M. T., Le, T. M., Lorinc, A. N., … Jordan, L. C. (2015). A multispecialty pediatric neurovascular conference: a model for interdisciplinary management of complex disease. Pediatric Neurology, 52(2), 165–73. -
GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas.
Majzner, R. G., Ramakrishna, S., Yeom, K. W., Patel, S., Chinnasamy, H., Schultz, L. M., … Monje, M. (2022). GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature. -
Stroke Mimics Are Not Benign in Immunocompromised Children.
Mahdi, J., Bach, A., Smith, A. E., Tomko, S. R., Fields, M. E., Griffith, J. L., … Agner, S. C. (2022). Stroke Mimics Are Not Benign in Immunocompromised Children. Stroke, 101161STROKEAHA122039311. -
MAJOR TUMOR REGRESSIONS IN H3K27M-MUTATED DIFFUSE MIDLINE GLIOMA (DMG) FOLLOWING SEQUENTIAL INTRAVENOUS (IV) AND INTRACEREBROVENTRICULAR (ICV) DELIVERY OF GD2-CAR T-CELLS
Monje, M., Majzner, R., Mahdi, J., Ramakrishna, S., Patel, S., Chinnasamy, H., … Mackall, C. (2022). MAJOR TUMOR REGRESSIONS IN H3K27M-MUTATED DIFFUSE MIDLINE GLIOMA (DMG) FOLLOWING SEQUENTIAL INTRAVENOUS (IV) AND INTRACEREBROVENTRICULAR (ICV) DELIVERY OF GD2-CAR T-CELLS. NEURO-ONCOLOGY. OXFORD UNIV PRESS INC. -
Major tumor regressions in H3K27M-mutated diffuse midline glioma (DMG) following sequential intravenous (IV) and intracerebroventricular (ICV) delivery of GD2-CAR T cells
Majzner, R. G., Mahdi, J., Ramakrishna, S., Patel, S., Chinnasamy, H., Yeom, K., … Mackall, C. L. (2022). Major tumor regressions in H3K27M-mutated diffuse midline glioma (DMG) following sequential intravenous (IV) and intracerebroventricular (ICV) delivery of GD2-CAR T cells. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH. -
Tumor inflammation-associated neurotoxicity.
Mahdi, J., Dietrich, J., Straathof, K., Roddie, C., Scott, B. J., Davidson, T. B., … Monje, M. (2023). Tumor inflammation-associated neurotoxicity. Nature Medicine. -
TUMOR INFLAMMATION-ASSOCIATED NEUROTOXICITY (TIAN): A TOXICITY SYNDROME IN PATIENTS TREATED WITH IMMUNOTHERAPY FOR CENTRAL NERVOUS SYSTEM TUMORS
Mahdi, J., Dietrich, J., Straathof, K., Roddie, C., Scott, B., Davidson, T. B., … Monje, M. (2023). TUMOR INFLAMMATION-ASSOCIATED NEUROTOXICITY (TIAN): A TOXICITY SYNDROME IN PATIENTS TREATED WITH IMMUNOTHERAPY FOR CENTRAL NERVOUS SYSTEM TUMORS. NEURO-ONCOLOGY. OXFORD UNIV PRESS INC.
Clinical Trials
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
Practice Locations
LPCH- Neurology (Palo Alto) Palo Alto, CA
Palo Alto, CAImportant Information about Our Organizations and Physician Affiliation
Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.
Referring Physicians
PHYSICIAN HELPLINE
Phone: 1-866-742-4811
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.
- Send referrals online
- Place radiology and lab orders
- View referral status
- Access medical records